Edition:
United Kingdom

Lexicon Pharmaceuticals Inc (LXRX.OQ)

LXRX.OQ on NASDAQ Stock Exchange Global Select Market

9.99USD
12 Dec 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$9.99
Open
$10.00
Day's High
$10.16
Day's Low
$9.78
Volume
216,648
Avg. Vol
240,330
52-wk High
$17.96
52-wk Low
$8.10

Chart for

About

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of... (more)

Overall

Beta: 0.15
Market Cap(Mil.): $1,239.53
Shares Outstanding(Mil.): 105.58
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-Biopharma Credit Says Enetered Into Term Loan Agreement For Up To US$200 Mln With Lexicon Pharmaceuticals

* BIOPHARMA CREDIT PLC SAYS ENETERED INTO A DEFINITIVE TERM LOAN AGREEMENT FOR UP TO US$200 MILLION WITH LEXICON PHARMACEUTICALS, INC. Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

05 Dec 2017

BRIEF-Lexicon Pharmaceuticals Secures Up To $200 Million Non-Dilutive Term Loan Financing

* LEXICON PHARMACEUTICALS SECURES UP TO $200 MILLION NON-DILUTIVE TERM LOAN FINANCING

05 Dec 2017

BRIEF-Lexicon Pharmaceuticals reports Q3 loss per share $0.29

* Lexicon Pharmaceuticals reports third quarter 2017 financial results and provides a business update

08 Nov 2017

BRIEF-Lexicon Pharmaceuticals initiates patient dosing in a phase 1 study of LX9211

* Lexicon Pharmaceuticals initiates patient dosing in a phase 1 study of LX9211 Source text for Eikon: Further company coverage:

27 Sep 2017

BRIEF-Lexicon Pharmaceuticals gets European Commission's approval for Xermelo

* European Commission approves Xermelo (Telotristat Ethyl) for the treatment of Carcinoid Syndrome Diarrhea in combination with somatostatin analog therapy

19 Sep 2017

BRIEF-Lexicon Pharma reports positive pooled continuous glucose monitoring data

* Lexicon Pharmaceuticals reports positive pooled continuous glucose monitoring data from pivotal phase 3 intandem1 and intandem2 studies of sotagliflozin

08 Sep 2017

BRIEF-Lexicon Pharmaceuticals reports data from pivotal phase 3 intandem2 study of sotagliflozin

* Lexicon Pharmaceuticals reports additional positive data from pivotal phase 3 intandem2 study of sotagliflozin

15 Aug 2017

BRIEF-Lexicon Pharmaceuticals reports opt-in decision for U.S. co-promotion of sotagliflozin with Sanofi in type 1 diabetes

* Lexicon Pharmaceuticals announces opt-in decision for u.s. Co-Promotion of sotagliflozin with Sanofi in type 1 diabetes

31 Jul 2017

BRIEF-Lexicon collaborator Ipsen receives positive CHMP opinion for Xermelo

* Lexicon collaborator Ipsen receives positive CHMP opinion for Xermelo® (telotristat ethyl) Source text for Eikon: Further company coverage:

21 Jul 2017

BRIEF-Lexicon Pharmaceuticals amends collaboration and license agreement

* Lexicon Pharmaceuticals - on july 1, 2017, entered into an amendment to collaboration and license agreement with Sanofi-Aventis Deutschland GMBH

07 Jul 2017

Competitors

Earnings vs. Estimates